Brain-Zapping ultrasound tested with drug in fight against recurrent cancer
NCT ID NCT07385846
Summary
This is a small, early-stage study to see if a combination treatment is safe for people with a specific type of recurrent brain cancer (glioblastoma). Doctors will use a focused ultrasound device to target the tumor area along with an immunotherapy drug called pembrolizumab. The main goal is to check for side effects, but researchers will also look for early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Cincinnati
Cincinnati, Ohio, 45219, United States
Contact
Conditions
Explore the condition pages connected to this study.